The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP.
about
Physiology and pharmacology of erythropoietinCharacterisation of intact recombinant human erythropoietins applied in doping by means of planar gel electrophoretic techniques and matrix-assisted laser desorption/ionisation linear time-of-flight mass spectrometry.Capillary electrophoresis and matrix-assisted laser desorption/ionization-time of flight-mass spectrometry for analysis of the novel erythropoiesis-stimulating protein (NESP).Glycosylation of therapeutic proteins: an effective strategy to optimize efficacyHigh-dose erythropoietin population pharmacokinetics in neonates with hypoxic-ischemic encephalopathy receiving hypothermia.Increased erythropoietin elimination in fetal sheep following chronic phlebotomyChange in erythropoietin pharmacokinetics following hematopoietic transplantation.Receptor-based dosing optimization of erythropoietin in juvenile sheep after phlebotomy.Population pharmacokinetics of darbepoetin alfa in haemodialysis and peritoneal dialysis patients after intravenous administrationCellular level models as tools for cytokine design.Emerging technologies in the delivery of erythropoietin for therapeutics.Treating anemia in heart failure patients: a review of erythropoiesis-stimulating agents.Pharmacokinetics and pharmacodynamics of pegfilgrastim.Assessment of the metabolism of therapeutic proteins and antibodies.Renal erythropoietin-producing cells in health and disease.Stabilization of bacterially expressed erythropoietin by single site-specific introduction of short branched PEG chains at naturally occurring glycosylation sites.Probing protease sensitivity of recombinant human erythropoietin reveals α3-α4 inter-helical loop as a stability determinant.In-vivo detection of the erythropoietin receptor in tumours using positron emission tomography.Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP).Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial.Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy.Pharmacokinetics of PEGylated Recombinant Human Erythropoietin in RatsReno-endocrinal disorders: A basic understanding of the molecular geneticsErythropoietin: recent developments in the treatment of spinal cord injuryA new principle suggested for detection of darbepoetin-alpha (NESP) doping.Sensitive and comprehensive analysis of O-glycosylation in biotherapeutics: a case study of novel erythropoiesis stimulating protein.High-level expression of secreted complex glycosylated recombinant human erythropoietin in the Physcomitrella Delta-fuc-t Delta-xyl-t mutant.Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients.Epoetin beta pegol, but not recombinant erythropoietin, retains its hematopoietic effect in vivo in the presence of the sialic acid-metabolizing enzyme sialidase.
P2860
Q26866945-98C4B623-114C-497A-A046-2584A39EDAD1Q33211610-514A3FDB-B837-4158-A9C5-2ADC67CDD02BQ33212718-345C0F41-EC44-4B41-8CBB-4FD043DC5BF5Q33586660-7197B8EE-91ED-417D-A13E-D4447D3C9473Q33812116-7E954203-265F-43BD-8EB6-EA78E898DE95Q33825425-AB1E05C0-AA73-408B-8581-3608CC8C1CE7Q33892534-3B9A486B-2C50-47B7-8BB2-30E3141469D6Q35079550-5FFFC1C6-8527-4615-BE2A-F428A7838993Q36025060-D7087F05-6C8C-4708-BE5D-AC784389EACBQ36393660-F9DCCE56-90BB-4B45-BB45-C3F2275FAE46Q37646523-11F05081-A1CA-488E-85C7-82F2DF33F941Q37765902-81170F76-111C-44AE-860A-9EEFE0C79545Q37860299-4F0DADC1-0929-4354-9829-EF4B6547F9F8Q38217623-4FE3CD99-967B-440C-BE1A-1F9186A219DAQ38531955-F526DDDE-28B5-4A01-A2B1-A220BB940EDCQ38802664-C25AABE3-29A1-4884-92CD-0E4F3FE20AEAQ38848944-3039F18A-9EE6-4380-913F-3653CF80B1E7Q38958980-F0674AA9-5CBE-491D-A378-48C34DFAF1D9Q40351752-587F29BD-E6B8-4F27-90CE-9841DAE747C0Q41469526-E76AC851-049B-4361-8E15-387C79B5187BQ41529847-676D207D-DAAC-4347-AF97-AA8C0DA3EA9BQ41911525-45F558F7-F26E-4B19-AD47-A5596C82BB60Q42564390-FE193DE6-6E3A-4459-B4B4-04DF7BC5CFF3Q42797884-E32E5B65-B3C4-468C-9DC9-D437B24CCF1CQ44786238-5170E7D0-843F-4C7A-9B3D-E083F43D31D5Q47787862-24B4A52E-56AD-4280-8655-3239ED21FC0FQ51048011-806B7A15-AB20-4392-9B93-82D03A049832Q53605929-410CDFB9-8006-4F84-BE54-1F46E56F55C6Q54173895-7A1B17CE-D3EA-4260-B4DC-AA7BBB3DD83A
P2860
The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The enigma of the metabolic fa ...... ombinant drugs rhEpo and NESP.
@ast
The enigma of the metabolic fa ...... ombinant drugs rhEpo and NESP.
@en
type
label
The enigma of the metabolic fa ...... ombinant drugs rhEpo and NESP.
@ast
The enigma of the metabolic fa ...... ombinant drugs rhEpo and NESP.
@en
prefLabel
The enigma of the metabolic fa ...... ombinant drugs rhEpo and NESP.
@ast
The enigma of the metabolic fa ...... ombinant drugs rhEpo and NESP.
@en
P1476
The enigma of the metabolic fa ...... ombinant drugs rhEpo and NESP.
@en
P2093
Wolfgang Jelkmann
P2860
P304
P356
10.1034/J.1600-0609.2002.02813.X
P577
2002-11-01T00:00:00Z